Exane Derivatives’s Elevance Health ELV Stock Holding History

Exane Derivatives’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	-$4.91K	–	843
2022 Q1	$4.91K	Hold	10	–	–	﹤0.01%	698
2021 Q4	$4.63K	Sell	10 -194	-95%	-$81.6K	﹤0.01%	624
2021 Q3	$76.1K	Buy	+204	New	+$77.5K	0.02%	571
2018 Q3	–	Sell	-10,138	Closed	-$2.41M	–	705
2018 Q2	$2.41M	Buy	+10,138	New	+$2.35M	0.4%	47
2015 Q2	–	Sell	-149,517	Closed	-$23.1M	–	532
2015 Q1	$23.1M	Buy	+149,517	New	+$21.3M	2.55%	2

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Exane Derivatives's ELV Position: Q2 2022 in Review

Exane Derivatives sold out of Elevance Health (ELV) in Q2 2022, closing a stake of 10 shares — an estimated $4.91K sold.

Exane Derivatives first reported a position in ELV in Q1 2015 and held it in 5 quarters. The position peaked at $23.1M in Q1 2015. 1,440 funds tracked by Wall St. Rank hold ELV as of Q2 2022.

Exane Derivatives reported no remaining Elevance Health position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 10 Elevance Health shares in Q2 2022, an estimated $4.91K.
Exane Derivatives first reported a position in Elevance Health in Q1 2015 and held it in 5 quarters.
Exane Derivatives's Elevance Health position peaked at $23.1M in Q1 2015.
1,440 funds tracked by Wall St. Rank held Elevance Health as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.